NCT02160587View on ClinicalTrials.gov

Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

PHASE1CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Surgical Site Infection
Interventions
DRUG

Chloraprep

ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.

DRUG

0.9% Physiological Saline

0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.

OTHER

ZuraPrep without IPA

ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation

Trial Locations (1)

59718

BioScience Laboratories, Inc., Bozeman

All Listed Sponsors
lead

Zurex Pharma, Inc.

INDUSTRY

NCT02160587 - Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA | Biotech Hunter | Biotech Hunter